Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAT 1306

Drug Profile

BAT 1306

Alternative Names: BAT1306

Latest Information Update: 31 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Developer Bio-Thera Solutions; Sun Yat-Sen University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 31 Dec 2019 Bio-Thera completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, second-line therapy or greater) in China (ChiCTR1900027506)
  • 15 Apr 2019 BioThera plans a phase II trial for Gastric cancer (First-line therapy, Late-stage disease) in China (ChiCTR1900022184)
  • 03 Apr 2019 The Shanghai East Hospital and Bio-thera Solutions plan a phase I/IIa trial for Solid tumours (Combination therapy) in China (ChiCTR1900022300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top